Citius Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CTXR)

$4.62 -0.15 (-3.14 %)
(As of 11/22/2017 04:10 AM ET)
Previous Close$4.77
Today's Range$4.58 - $5.19
52-Week Range$2.55 - $14.85
Volume139,500 shs
Average Volume34,445 shs
Market Capitalization$40.75 million
P/E RatioN/A
Dividend YieldN/A
Beta2525.86

About Citius Pharmaceuticals (NASDAQ:CTXR)

Citius Pharmaceuticals logoCitius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Pharmaceuticals - NEC
  • Symbol: NASDAQ:CTXR
  • CUSIP: N/A
  • Web: www.citiuspharma.com
Profitability:
  • Trailing EPS: ($2.01)
  • Return on Equity: -75.95%
  • Return on Assets: -45.30%
Misc:
  • Outstanding Shares: 8,250,000
 

Frequently Asked Questions for Citius Pharmaceuticals (NASDAQ:CTXR)

What is Citius Pharmaceuticals' stock symbol?

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work?

Shares of Citius Pharmaceuticals reverse split on the morning of Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

Who are some of Citius Pharmaceuticals' key competitors?

Who are Citius Pharmaceuticals' key executives?

Citius Pharmaceuticals' management team includes the folowing people:

  • Leonard L. Mazur, Executive Chairman of the Board, Secretary (Age 71)
  • Myron Z. Holubiak, President, Chief Executive Officer, Director (Age 69)
  • Suren G. Dutia, Director (Age 72)
  • Eugene Holuka, Director (Age 57)
  • William J. Kane, Director (Age 72)
  • Howard Safir, Director (Age 75)
  • Carol A. Webb, Director (Age 69)

How do I buy Citius Pharmaceuticals stock?

Shares of Citius Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Citius Pharmaceuticals' stock price today?

One share of Citius Pharmaceuticals stock can currently be purchased for approximately $4.62.

How big of a company is Citius Pharmaceuticals?

Citius Pharmaceuticals has a market capitalization of $40.75 million.

How can I contact Citius Pharmaceuticals?

Citius Pharmaceuticals' mailing address is 11 Commerce Dr Fl 1, CRANFORD, NJ 07016-3501, United States. The company can be reached via phone at +1-908-9676676.


MarketBeat Community Rating for Citius Pharmaceuticals (NASDAQ CTXR)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  17 (Vote Underperform)
Total Votes:  34
MarketBeat's community ratings are surveys of what our community members think about Citius Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Citius Pharmaceuticals (NASDAQ:CTXR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Citius Pharmaceuticals (NASDAQ:CTXR)

Price Target History for Citius Pharmaceuticals (NASDAQ:CTXR)

Analysts' Ratings History for Citius Pharmaceuticals (NASDAQ:CTXR)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Citius Pharmaceuticals (NASDAQ:CTXR)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Citius Pharmaceuticals (NASDAQ:CTXR)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Citius Pharmaceuticals (NASDAQ:CTXR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Citius Pharmaceuticals (NASDAQ CTXR)

Insider Trades by Quarter for Citius Pharmaceuticals (NASDAQ:CTXR)

Insider Trades by Quarter for Citius Pharmaceuticals (NASDAQ CTXR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2017Leonard L MazurInsiderBuy11,000$2.68$29,480.00View SEC Filing  
8/8/2017Leonard L MazurInsiderBuy421,400$4.13$1,740,382.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Citius Pharmaceuticals (NASDAQ CTXR)

Source:
DateHeadline
Inserting And Removing Central Venous Catheters Cause Significant Discomfort In Cancer Patients And At Times Is UnnecessaryInserting And Removing Central Venous Catheters Cause Significant Discomfort In Cancer Patients And At Times Is Unnecessary
finance.yahoo.com - November 14 at 6:03 PM
International Study at MD Anderson Sister Institutions Supports Mino Lok™ Phase 2b Results: Poster Presented at ID WeekInternational Study at MD Anderson Sister Institutions Supports Mino Lok™ Phase 2b Results: Poster Presented at ID Week
finance.yahoo.com - November 8 at 12:38 AM
Is Citius Pharmaceuticals Inc’s (CTXR) Balance Sheet Strong Enough To Weather A Storm?Is Citius Pharmaceuticals Inc’s (CTXR) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - October 31 at 11:51 PM
Citius Pharmaceuticals, Inc. Receives "Fast Track" Designation By FDA For Mino-Lok™ Investigational TrialCitius Pharmaceuticals, Inc. Receives "Fast Track" Designation By FDA For Mino-Lok™ Investigational Trial
finance.yahoo.com - October 31 at 6:49 PM
Citius Pharmaceuticals to Present at the Dawson James 2017 Small Cap Growth Stock ConferenceCitius Pharmaceuticals to Present at the Dawson James 2017 Small Cap Growth Stock Conference
finance.yahoo.com - October 17 at 6:25 PM
Citius Pharmaceuticals (CTXR) Discusses Recent developments, Financial Results in Shareholder LetterCitius Pharmaceuticals (CTXR) Discusses Recent developments, Financial Results in Shareholder Letter
www.streetinsider.com - October 12 at 5:14 AM
Citius Pharmaceuticals Issues Shareholder LetterCitius Pharmaceuticals Issues Shareholder Letter
finance.yahoo.com - October 11 at 7:09 PM
Why Citius Pharmaceuticals Looks UndervaluedWhy Citius Pharmaceuticals Looks Undervalued
finance.yahoo.com - October 3 at 6:32 AM
Citius Pharmaceuticals (CTXR) Reports Phase 3 Update On Mino-Lok Clinical Trial Following FDA MeetingCitius Pharmaceuticals (CTXR) Reports Phase 3 Update On Mino-Lok Clinical Trial Following FDA Meeting
www.streetinsider.com - September 6 at 12:11 AM
Citius Pharmaceuticals, Inc. Provides Phase 3 Update On Mino-Lok™ Clinical Trial Following FDA MeetingCitius Pharmaceuticals, Inc. Provides Phase 3 Update On Mino-Lok™ Clinical Trial Following FDA Meeting
finance.yahoo.com - September 5 at 8:00 AM
Citius Pharmaceuticals Inc (CTXR) Insider Leonard L. Mazur Purchases 11,000 SharesCitius Pharmaceuticals Inc (CTXR) Insider Leonard L. Mazur Purchases 11,000 Shares
www.americanbankingnews.com - August 28 at 10:22 PM
Insider Buying: Citius Pharmaceuticals Inc (NASDAQ:CTXR) Insider Acquires 421,400 Shares of StockInsider Buying: Citius Pharmaceuticals Inc (NASDAQ:CTXR) Insider Acquires 421,400 Shares of Stock
www.americanbankingnews.com - August 10 at 10:38 PM

Social Media

Financials

Chart

Citius Pharmaceuticals (NASDAQ CTXR) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.